According to @StockMKTNewz, the US FDA approved the first-ever GLP-1 pill for weight loss from Wegovy maker Novo Nordisk (NVO), as reported by CNBC. This establishes the first oral GLP-1 option for obesity treatment and marks a major regulatory catalyst for NVO, per @StockMKTNewz citing CNBC. The source post did not provide label details, pricing, launch timing, or market reaction data, and it did not mention any cryptocurrency impacts, according to @StockMKTNewz.